This was also confirmed in the clinical scenario, as it has been shown that AITL and PTCL-NOS TFH are present in a quarter to half of the cases of mutations in TET2 [10,76,77]. The gene discussed is TET2; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.